一种新的蒽环素类抗生素阿克拉霉素A的第I期临床试验用于22例晚期癌症患者,采用毒天静注连续5天每4周重复一次的给药方案.这样所产生的有限毒性是轻度的骨髓抑制,30mg/m~2连续5天骨髓抑制则是严重的.在首次给药后大约11天,发现血小板的减少比白细胞更显著,在第21天白细胞缺乏症出现最严重.一些病人出现中度恶心呕吐.未发现对肝 Phase I clinical trial of a new anthracycline antibiotic, aclacinomycin A, was used in 22 patients with advanced cancer who dosed intravenously daily for 4 days for 5 consecutive days. Limited toxicity is mild myelosuppression, with myelosuppression at 30 mg / m 2 for 5 consecutive days is severe.About 11 days after the first dose, a reduction in platelets was found to be more pronounced than leukocytes, with leukocyte deficiency occurring on day 21 The most serious. Some patients with moderate nausea and vomiting. No liver was found